Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
PROACC-1 trial: what clinicians have said so far
Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15
- NCT05546476 ↗
- Completed
- Pfizer
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on PROACC-1 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PROACC-1 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER, CACHEXIA, AND ELEVATED CONCENTRATIONS OF GDF-15, FOLLOWED BY AN OPTIONAL OPEN-LABEL TREATMENT PERIOD (PROACC -1)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Non-small Cell Lung Cancer; Pancreatic Cancer; Colorectal Cancer; Loss of Appetite; Fatigue; Cachexia
- Interventions
- ponsegromab; Placebo for ponsegromab
- Arms
- Double-Blind ponsegromab Treatment low dose followed by Open Label ponsegromab Treatment · Experimental
- Double-Blind Placebo Treatment followed by Open-Label ponsegromab Treatment · Placebo comparator
- Double-Blind ponsegromab Treatment medium dose followed by Open Label ponsegromab Treatment · Experimental
- Double-Blind ponsegromab Treatment high dose followed by Open Label ponsegromab Treatment · Experimental
- Enrollment
- 187
- Primary outcomes
- Part A: Change From Baseline in Body Weight at Week 12
- Sponsor
- Pfizer
- Start
- Nov 21, 2022
- Primary completion
- Mar 13, 2024
- Results posted
- Yes
- Registry record
- NCT05546476 · updated Jun 3, 2026
Publications
linked from the registry- Groarke JD, Crawford J, Collins SM, Lubaczewski S, Roeland EJ, Naito T, Hendifar AE, Fallon M, Takayama K, Asmis T, Dunne RF, Karahanoglu I, Northcott CA, Harrington MA, Rossulek M, Qiu R, Saxena AR. Ponsegromab for the Treatment of Cancer Cachexia. N Engl J Med. 2024 Dec 19;391(24):2291-2303. doi: 10.1056/NEJMoa2409515. Epub 2024 Sep 14. PubMed 39282907
- Groarke JD, Crawford J, Collins SM, Lubaczewski SL, Breen DM, Harrington MA, Jacobs I, Qiu R, Revkin J, Rossulek MI, Saxena AR. Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC-1 study design. J Cachexia Sarcopenia Muscle. 2024 Jun;15(3):1054-1061. doi: 10.1002/jcsm.13435. Epub 2024 Mar 18. PubMed 38500292